Design Therapeutics Investor Relations Material

Design Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nucleotide repeat expansions. Their innovative approach centers on the development of GeneTAC™ gene targeted chimera small molecules. These molecules are designed to modulate the expression of disease-causing genes, offering potential treatments for a range of genetic disorders. The company's research portfolio includes projects targeting conditions such as Friedreich Ataxia, a severe progressive multi-system disease; Myotonic Dystrophy Type-1 (DM1), affecting muscle, heart, and other organs; and other nucleotide repeat expansion-driven diseases like Fragile X syndrome and Huntington disease. The company is headquartered in Carlsbad, California, and its shares are listed on the Nasdaq.